Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics

被引:7
|
作者
Fattahi, Hassan [1 ,2 ,3 ]
Laurent, Sophie [1 ,2 ]
Liu, Fujun [1 ,2 ]
Arsalani, Nasser [3 ]
Elst, Luce Vander [1 ,2 ]
Muller, Robert N. [1 ,2 ]
机构
[1] Univ Mons, Dept Gen Organ & Biomed Chem, NMR, B-7000 Mons, Belgium
[2] Univ Mons, Mol Imaging Lab, B-7000 Mons, Belgium
[3] Univ Tabriz, Polymer Res Lab, Dept Organ & Biochem, Fac Chem, Tabriz, Iran
关键词
contrast agent; drug delivery; hyperthermia; magnetoliposome; molecular imaging; MRI; nanomedicine; superparamagnetic iron oxide nanoparticles; theragnostics; IRON-OXIDE NANOPARTICLES; IN-VIVO; DRUG-DELIVERY; MAGNETIC NANOPARTICLES; SUPERPARAMAGNETIC LIPOSOMES; CATIONIC MAGNETOLIPOSOMES; STEM-CELLS; THERAPY; MRI; NANOMEDICINE;
D O I
10.2217/NNM.11.14
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In the emerging field of molecular and cellular imaging, flexible strategies to synthesize multimodal contrast agents with targeting ligands are required. Liposomes have the ability to combine with a large variety of nanomaterials, including superparamagnetic iron oxide nanoparticles, to form magnetoliposomes (MLs). MLs can be used as highly efficient MRI contrast agents. Owing to their high flexibility, MLs can be associated with other imaging modality probes to be used as multimodal contrast agents. By using a thermosensitive lipid bilayer in the ML structure, these biocompatible systems offer many possibilities for targeting and delivering therapeutic agents for 'theragnostics', a coincident therapy and diagnosis strategy. This article deals with the fast-growing field of MLs as biomedical diagnostic tools. Different kinds of MLs, their preparation methods, as well as their surface modification with different imaging probes, are discussed. ML applications as multimodal contrast agents and in theragnostics are reviewed. Some important issues for the biomedical uses of magnetic liposomes, such as toxicity, are summarized.
引用
收藏
页码:529 / 544
页数:16
相关论文
共 50 条
  • [21] Colloidal tetrapyrroles as high contrast, multimodal biomedical imaging agents
    Lovell, Jonathan F.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [22] Nanoparticle Loaded Polymeric Microbubbles as Contrast Agents for Multimodal Imaging
    Teraphongphom, Nutte
    Chhour, Peter
    Eisenbrey, John R.
    Naha, Pratap C.
    Witschey, Walter R. T.
    Opasanont, Borirak
    Jablonowski, Lauren
    Cormode, David P.
    Wheatley, Margaret A.
    LANGMUIR, 2015, 31 (43) : 11858 - 11867
  • [23] Nanosized Contrast Agents in Ultrasound Molecular Imaging
    Zeng, Fengyi
    Du, Meng
    Chen, Zhiyi
    Frontiers in Bioengineering and Biotechnology, 2021, 9
  • [24] Mapping PVS by Molecular Imaging with Contrast Agents
    Kang, Kyung A.
    PRIMO VASCULAR SYSTEM: ITS ROLE IN CANCER AND REGENERATION, 2012, : 227 - 234
  • [25] Ultrasound Contrast Agents For Ultrasound Molecular Imaging
    Tranquart, F.
    Arditi, M.
    Bettinger, T.
    Frinking, P.
    Hyvelin, J. M.
    Nunn, A.
    Pochon, S.
    Tardy, I.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2014, 52 (11): : 1268 - 1276
  • [26] Molecular imaging with targeted ultrasound contrast agents
    Lanza, G
    Hall, C
    Scott, M
    Fuhrhop, R
    Marsh, J
    Wickline, S
    2000 IEEE ULTRASONICS SYMPOSIUM PROCEEDINGS, VOLS 1 AND 2, 2000, : 1917 - 1926
  • [27] Nanoparticulate Contrast Agents for Multimodality Molecular Imaging
    Xia, Yang
    Matham, Murukeshan Vadakke
    Su, Haibin
    Padmanabhan, Parasuraman
    Gulyas, Balazs
    JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2016, 12 (08) : 1553 - 1584
  • [28] Future contrast agents for molecular imaging in stroke
    Heckl, Stefan
    CURRENT MEDICINAL CHEMISTRY, 2007, 14 (16) : 1713 - 1728
  • [29] Nanosized Contrast Agents in Ultrasound Molecular Imaging
    Zeng, Fengyi
    Du, Meng
    Chen, Zhiyi
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2021, 9
  • [30] MR contrast agents for molecular and cellular imaging
    Bulte, JWM
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2004, 5 (06) : 483 - 483